“…β-Sitosterol (5a) inhibited human breast MCF-7 and MDA-MB-231 adenocarcinoma cells [26], used for the treatment of benign prostatic hyperplasia [27], chemopreventive potential against colon cancer [28], attenuated β-catenin and PCNA expression, inhibited the expression of NPC1L1 [29], induced apoptosis mediated by the activation of ERK and down regulated Akt in MCA-102 murine fibrosarcoma cells [30]. Stigmasterol (5b) showed therapeutic efficacy against Ehrlich ascites carcinoma in mice [31], lowered plasma cholesterol levels, inhibited intestinal cholesterol and plant sterol absorption, suppressed hepatic cholesterol and classic bile acid synthesis in Winstar and WKY rats [32], exhibited cytostatic activity against Hep-2 and McCoy cells [33], markedly inhibited tumour promotion in two stage carcinogenesis experiments [34] and exhibited antimutagenic [35], topical antiinflammatory [36], antiosteoarthritic [37] and antioxidant [38] activities.…”